Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00461292 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 275
- Enrollment target
NCT00461292 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 275 participants.
The verdict
NCT00461292, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 275 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A in treating overactive bladder in spinal cord injury or multiple sclerosis patients
Interventions
- BIOLOGICAL botulinum toxin Type A (200U)
- BIOLOGICAL botulinum toxin Type A (300U)
- OTHER Normal saline (Placebo); botulinum toxin Type A (200U)
- OTHER Normal saline (Placebo); botulinum toxin Type A (300U)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 275 participants |
| Start Date | 2007-05 |
| Est. Completion | 2010-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00461292
The ClinicalTrials.gov registry entry for NCT00461292 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 275 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which botulinum toxin Type A (200U) is the first listed.
NCT00461292 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00461292 about?
NCT00461292 is a clinical study titled "Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder". The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A in treating overactive bladder in spinal cord injury or multiple sclerosis patients
What is the current status of trial NCT00461292?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 275 participants. The study started on 2007-05. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00461292?
The interventions under investigation include: botulinum toxin Type A (200U) (BIOLOGICAL), botulinum toxin Type A (300U) (BIOLOGICAL), Normal saline (Placebo); botulinum toxin Type A (200U) (OTHER), Normal saline (Placebo); botulinum toxin Type A (300U) (OTHER).
Who is sponsoring clinical trial NCT00461292?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.